Drug resistant strains of human cytomegalovirus (HCMV) in patients at risk may increasingly
develop into a problem in the clinical setting. Genotypic resistance testing is becoming the …

Infections due to resistant human cytomegalovirus (CMV) are an emerging problem,
particularly in immunocompromised hosts. When managing such patients, clinicians should …

An increasing volume of information correlating CMV genotypes and drug susceptibility
phenotypes is becoming available. This will improve the interpretation of sequence-based …

Drug‐resistant cytomegalovirus (CMV) should be considered when viral shedding persists
after several weeks of therapy. The problem is most likely to arise in the setting of a severely …

The study of human cytomegalovirus (HCMV) antiviral drug resistance has enhanced
knowledge of the virological targets and the mechanisms of antiviral activity. The currently …

Human cytomegalovirus (HCMV) resistance to antivirals is a major problem in
immunocompromised patients. Drug resistance is characterized by phenotypic testing or …

ABSTRACT A number of specific point mutations in the human cytomegalovirus (HCMV)
DNA polymerase (UL54) gene have been tentatively associated with decreased …

The emergence of human cytomegalovirus (HCMV) drug resistant strains is a life-
threatening condition in immunocompromised individuals with active HCMV infection …

Antiviral therapy for cytomegalovirus (CMV) plays an important role in the clinical
management of solid organ and hematopoietic stem cell transplant recipients. However …

Cytomegalovirus (CMV) drug resistance mutation maps are updated with recent information
for polymerase inhibitors, the terminase inhibitor letermovir and the UL97 kinase inhibitor …